Chemotherapy dose intensity reductions due to adverse drug reactions in an oncology outpatient setting

Abstract

Objective. The aim of this study was to establish the incidence of adverse drug reactions (ADRs) that prevent administration of planned dose intensity antineoplastic chemotherapy in clinical practice.

Methods. A retrospective cohort study was made of adult oncology patients who received intravenous chemotherapy in an outpatient ward during 2005. Dose delays, dose reductions, dose omissions, or treatment discontinuations with respect to the planned chemotherapy regimen were obtained, and causes were evaluated to identify ADRs.

Results. A total of 532 patients were included, involving the administration of 631 chemotherapy regimens. The total number of cycles evaluated was 3553. The incidence of nonadherence to planned treatment due to ADRs was 12.9% cycles (95% CI: 11.8—14.0). Differences according to patient’s age were found, patients younger than 65 years showed higher rates of nonadherence due to ADRs. Myelosuppression was the main cause of dose delays, and gastrointestinal and neurological toxicity were reported as the main causes of dose reductions.

Conclusions. The incidence of ADRs preventing planned dose intensity administration has been estimated. Follow-up of nonadherence to antineoplastic chemotherapy prescriptions can be used to evaluate tolerance in the clinical setting. Continuous evaluation of security in clinical practice provides information on benefits outweighing the deleterious effects in specific patient populations where the available data are limited.

Keywords

adverse drug reaction antineoplastic chemotherapy dose intensity

Get full access to this article

View all access options for this article.

References

Hryniuk W. , Levine MN Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162-70.

Lyman GH , Dale DC , Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study community practices. J Clin Oncol 2003; 21: 4524-31.

Ladewinski LA , Belknap SM , Nebeker JR , Sartor O. , Lyons A. , Kuzel TC et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 2003; 21: 3589-66.

Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.

Poole SG , Dooley MJ Establishing a baseline incidence of adverse drug reactions in hospitalised oncology patients. J Oncol Pharm Practice 2000; 6: 55-9.

Lewis JH , Kilgore ML , Goldman DP , Trimble EL , Kaplan R. , Montello MJ et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-9.

Yancik R. , Ries LAG. Cancer in older persons: an international issue in an ageing world . Semin Oncol 2004; 31: 128-36.

Tam JT , Payne J. , Teplitzky B. , Ershler W. , Balducci L. Perceptions of clinical trial participation between community practitioners and older cancer patients. J Clin Oncol 2004 ; 22(14): 8260.

Lichtman SM Chemotherapy in the elderly. Semin Oncol 2004 ; 31: 160-74.

10.

Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 DCTD, NCI, NHI, DHHS. March 31, 2003. Available at: http://ctep.cancer.gov (accessed 13 November 2009).

11.

Bloechl-Daum B. , Deuson RR , Mavros P. , Hansen M. , Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006; 24: 4472-8.

12.

Bonadonna G. , Valagussa O. , Moliterni A. , Zambetti M. , Brambilla C.

Adjuvant cyclophospamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up

N Eng Med J 1995; 332: 901-6.

13.

De Maio E. , Gravina A. , Pacilio C. , Amabile G. , Labonia V. , Landi G. et al. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Med Res Methodol 2005; 5: 30.

14.

Wildiers H. Mastering chemotherapy dose reduction in elderly cancer patients. Eur J Cancer 2007; 43: 2235-41.